Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.72 |
| ▸ | THRB | P10828 | 13/20 | 0.42 |
| ▸ | THRA | P10827 | 11/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7052325 | 0.92 | NR3C1 (0.84) | NR3C1THRBTHRAHPGDCYP1A2 | |
| SCHEMBL7681978 | 0.92 | NR3C1 (0.71) | NR3C1THRBTHRAHPGDCYP1A2 | |
| SCHEMBL7053405 | 0.91 | NR3C1 (0.68) | NR3C1THRBTHRALMNAMAPT | |
| SCHEMBL5630623 | 0.91 | NR3C1 (0.85) | NR3C1THRBTHRACYP1A2CYP2C19 | |
| SCHEMBL7052767 | 0.90 | NR3C1 (0.62) | NR3C1THRBTHRAHPGDMAPT | |
| SCHEMBL7050206 | 0.90 | NR3C1 (0.62) | NR3C1THRBTHRACYP1A2CYP2C19 | |
| SCHEMBL7687151 | 0.90 | NR3C1 (0.62) | NR3C1THRBTHRAMAPTRORC | |
| SCHEMBL7051459 | 0.90 | NR3C1 (0.59) | NR3C1THRBTHRA | |
| SCHEMBL7688423 | 0.90 | NR3C1 (0.69) | NR3C1THRBTHRAHPGDCYP1A2 | |
| SCHEMBL7052864 | 0.90 | NR3C1 (0.69) | NR3C1THRBTHRACYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1102739-B1 | GLUCOCORTICOID AND THYROID HORMONE RECEPTOR LIGANDS FOR THE TREATMENT OF METABOLIC DISORDERS | KAROBIO AB (SE) | 2003-04-23 | — | — | EP | claimed |
| US-6492424-B1 | Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders | KARO BIO AB (SE) | 2002-12-10 | — | — | US | claimed |
| EP-1102739-A1 | GLUCOCORTICOID AND THYROID HORMONE RECEPTOR LIGANDS FOR THE TREATMENT OF METABOLIC DISORDERS | KARO BIO AB (SE) | 2001-05-30 | — | — | EP | claimed |
| WO-2000007972-A1 | GLUCOCORTICOID AND THYROID HORMONE RECEPTOR LIGANDS FOR THE TREATMENT OF METABOLIC DISORDERS | KARO BIO AB (SE) | 2000-02-17 | — | — | WO | claimed |
| US-20030166725-A1 | Compounds active at the glucocorticoid receptor | KARO BIO AB (SE) | 2003-09-04 | — | — | US | disclosed |
| EP-1102739-B1 | GLUCOCORTICOID AND THYROID HORMONE RECEPTOR LIGANDS FOR THE TREATMENT OF METABOLIC DISORDERS | KAROBIO AB (SE) | 2003-04-23 | — | — | EP | disclosed |
| EP-1265839-A1 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR | KARO BIO AB (SE) | 2002-12-18 | — | — | EP | disclosed |
| US-6492424-B1 | Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders | KARO BIO AB (SE) | 2002-12-10 | — | — | US | disclosed |
| EP-1143948-A3 | LIVER-SELECTIVE GLUCOCORTICOID ANTAGONIST FOR TREATING DIABETES | KARO BIO AB (SE) | 2002-09-11 | — | — | EP | disclosed |
| WO-2002044120-A1 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR III | KARO BIO AB (SE) | 2002-06-06 | — | — | WO | disclosed |
| EP-1143948-A2 | LIVER-SELECTIVE GLUCOCORTICOID ANTAGONIST FOR TREATING DIABETES | KARO BIO AB (SE) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001047859-A1 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR | KARO BIO AB (SE) | 2001-07-05 | — | — | WO | disclosed |
| EP-1102739-A1 | GLUCOCORTICOID AND THYROID HORMONE RECEPTOR LIGANDS FOR THE TREATMENT OF METABOLIC DISORDERS | KARO BIO AB (SE) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000007972-A1 | GLUCOCORTICOID AND THYROID HORMONE RECEPTOR LIGANDS FOR THE TREATMENT OF METABOLIC DISORDERS | KARO BIO AB (SE) | 2000-02-17 | — | — | WO | disclosed |
| WO-1999063976-A2 | LIVER-SELECTIVE GLUCOCORTICOID ANTAGONIST FOR TREATING DIABETES | KARO BIO AB (SE) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166725-A1 | Compounds active at the glucocorticoid receptor | NR3C1, NR3C2, GPR119 | NR3C1 1/4885THRB 167/4885THRA 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.